Comment on: British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of rheumatoid arthritis (after the first 2 years): reply by Luqmani, R, Oliver, S, Bosworth, A, Homers, D, Deighton, C

Influence of information provided prior to switching from Humira to biosimilar adalimumab on UK patients’ satisfaction: a cross-sectional survey by patient organisations by Kaneko, K, Prieto Alhambra, D, Jacklin, C, Bosworth, A, Dickinson, S, Berry, S, McAteer, H, Taylor, PC

Exploring the potential of iminosugars as antivirals for Crimean-Congo haemorrhagic fever virus, using the surrogate Hazara virus: liquid-chromatography-based mapping of viral N-gl... by Tyrrell, BE, Kumar, A, Gangadharan, B, Alonzi, D, Brun, J, Hill, M, Bharucha, T, Bosworth, A, Graham, V, Dowall, S, Miller, JL, Zitzmann, N

BSR and BHPR rheumatoid arthritis guidelines on eligibility criteria for the first biological therapy (vol 49, pg 1197, 2010) by Deighton, C, Hyrich, K, Ding, T, Ledingham, J, Lunt, M, Luqmani, R, Kiely, P, Bukhari, M, Abernethy, R, Ostor, A, Bosworth, A, Gadsby, K, McKenna, F, Finney, D, Dixey, J

BSR and BHPR guidelines on the use of rituximab in rheumatoid arthritis. by Bukhari, M, Abernethy, R, Deighton, C, Ding, T, Hyrich, K, Lunt, M, Luqmani, R, Kiely, P, Bosworth, A, Ledingham, J, Ostör, A, Gadsby, K, McKenna, F, Finney, D, Dixey, J

British Society for Rheumatology and british health professionals in Rheumatology guideline for the management of rheumatoid arthritis (the first two years). by Luqmani, R, Hennell, S, Estrach, C, Birrell, F, Bosworth, A, Davenport, G, Fokke, C, Goodson, N, Jeffreson, P, Lamb, E, Mohammed, R, Oliver, S, Stableford, Z, Walsh, D, Washbrook, C, Webb, F

BSR and BHPR rheumatoid arthritis guidelines on eligibility criteria for the first biological therapy. by Deighton, C, Hyrich, K, Ding, T, Ledingham, J, Lunt, M, Luqmani, R, Kiely, P, Bukhari, M, Abernethy, R, Ostor, A, Bosworth, A, Gadsby, K, McKenna, F, Finney, D, Dixey, J

BSR and BHPR rheumatoid arthritis guidelines on eligibility criteria for the first biological therapy. by Deighton, C, Hyrich, K, Ding, T, Ledingham, J, Lunt, M, Luqmani, R, Kiely, P, Bukhari, M, Abernethy, R, Ostor, A, Bosworth, A, Gadsby, K, McKenna, F, Finney, D, Dixey, J

BSR and BHPR rheumatoid arthritis guidelines on safety of anti-TNF therapies. by Ding, T, Ledingham, J, Luqmani, R, Westlake, S, Hyrich, K, Lunt, M, Kiely, P, Bukhari, M, Abernethy, R, Bosworth, A, Ostor, A, Gadsby, K, McKenna, F, Finney, D, Dixey, J, Deighton, C

British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of rheumatoid arthritis (after the first 2 years). by Luqmani, R, Hennell, S, Estrach, C, Basher, D, Birrell, F, Bosworth, A, Burke, F, Callaghan, C, Candal-Couto, J, Fokke, C, Goodson, N, Homer, D, Jackman, J, Jeffreson, P, Oliver, S, Reed, M, Sanz, L, Stableford, Z, Taylor, P, Todd, N, Warburton, L, Washbrook, C, Wilkinson, M

Arthritis prevention in the pre-clinical phase of RA with abatacept (the APIPPRA study): a multi-centre, randomised, double-blind, parallel-group, placebo-controlled clinical trial... by Al-Laith, M, Jasenecova, M, Abraham, S, Bosworth, A, Bruce, I, Buckley, C, Ciurtin, C, D'Agostino, M, Emery, P, Gaston, H, Isaacs, J, Filer, A, Fisher, B, Huizinga, T, Ho, P, Jacklin, C, Lempp, H, McInnes, I, Pratt, A, Östor, A, Raza, K, Taylor, P, Van Schaardenburg, D, Shivapatham, D, Wright, A, Vasconcelos, J, Kelly, J, Murphy, C, Prevost, A, Cope, A